| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 113 |
| 1 | METHOTREXATE | 102 |
| 2 | TOCILIZUMAB | 96 |
| 3 | INFLIXIMAB | 82 |
| 4 | ADALIMUMAB | 79 |
| 5 | TOFACITINIB | 73 |
| 6 | ADALIMUMAB-ADAZ | 70 |
| 7 | ADALIMUMAB-AATY | 69 |
| 8 | ADALIMUMAB-FKJP | 69 |
| 9 | ANAKINRA | 59 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TRIAMCINOLONE HEXACETONIDE | 38 | 0.1450 |
| 1 | TETANUS IMMUNE GLOBULIN (HUMAN) | 8 | 0.0734 |
| 2 | SILTUXIMAB | 30 | 0.0462 |
| 3 | CANAKINUMAB | 49 | 0.0045 |
| 4 | TOFACITINIB CITRATE | 52 | 0.0039 |
| 5 | DEFLAZACORT | 9 | 0.0035 |
| 6 | ANAKINRA | 59 | 0.0035 |
| 7 | INTERLEUKIN-10 | 1 | 0.0028 |
| 8 | NAPROXEN SODIUM 220MG | 34 | 0.0025 |
| 9 | DINUTUXIMAB | 2 | 0.0023 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 112 |
| 1 | Folate Analog Metabolic Inhibitor [EPC] | 102 |
| 2 | Interleukin-6 Receptor Antagonist [EPC] | 96 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 91 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 60 |
| 5 | Interleukin-1 Receptor Antagonist [EPC] | 59 |
| 6 | Calcineurin Inhibitor Immunosuppressant [EPC] | 56 |
| 7 | Alkylating Drug [EPC] | 52 |
| 8 | Aminosalicylate [EPC] | 46 |
| 9 | Vitamin B12 [EPC] | 45 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-6 Antagonist [EPC] | 30 | 0.0462 |
| 1 | Interleukin-1 Receptor Antagonist [EPC] | 59 | 0.0035 |
| 2 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 2 | 0.0018 |
| 3 | Human Immunoglobulin G [EPC] | 32 | 0.0015 |
| 4 | Interleukin-6 Receptor Antagonist [EPC] | 96 | 0.0007 |
| 5 | Tissue-nonspecific Alkaline Phosphatase [EPC] | 7 | 0.0007 |
| 6 | Carnitine Analog [EPC] | 2 | 0.0005 |
| 7 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 8 | Aminosalicylate [EPC] | 46 | 0.0005 |
| 9 | Calcineurin Inhibitor Immunosuppressant [EPC] | 56 | 0.0004 |